IGF1R and prostate carcinoma: To our knowledge, only one anti-cancer MoAb, anti-IGF-IR antibody A12 against the androgen-independent prostate cancer cell line LaCaP 35 V, has been reported to result in G2/M delay although its molecular mechanism is not yet understood [15].